WaveMan
WaveMan · Company
VCYT · Veracyte, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VCYT Veracyte (VCYT) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001384101
Quote by TradingView
Congress · 1Form 144 · 7
Insider buyers, 180 days
0
Funds added, last quarter
211
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $5.6M priced

What the filings say about VCYT

Insiders, 180 days
-$11.5M net sold
10 sellers · 45% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: purchase, 2026-03-03
Planned sales (Form 144), 90 days
$1.8M
7 notices

Veracyte insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, VERACYTE, INC. insiders sold a net $11.5M of stock across 173 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bhanji Muna
Director
SELL
2026-10-20 SECtraded 2026-10-19
1,864
$81.5K
+8.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 1, 2026.
  • The trade is 4.6% of the 40,854 shares held after it.
  • 1 other insider sold within 30 days.
  • 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bhanji Muna sold about $81.5K of VCYT under a 10b5-1 plan on Oct 19, 2026; 1 other insider sold within 30 days and 211 funds added in the latest 13F quarter.
Leite John
Global Chief Commercial Off
SELL
2026-09-22 SECtraded 2026-09-21
4,015
$160.6K
+14.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jun 4, 2026.
  • The trade is 3.2% of the 124,329 shares held after it.
  • 5 other insiders sold within 30 days.
  • 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Global Chief Commercial Off Leite John sold about $160.6K of VCYT under a 10b5-1 plan on Sep 21, 2026; 5 other insiders sold within 30 days and 211 funds added in the latest 13F quarter.
Holstein Jens
Director
SELL
2026-09-16 SECtraded 2026-09-14
5,000
$204.7K
+23.9%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Nov 20, 2025.
  • The trade is 18.2% of the 27,471 shares held after it.
  • 5 other insiders sold within 30 days.
  • 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Holstein Jens sold about $204.7K of VCYT under a 10b5-1 plan on Sep 14, 2026; 5 other insiders sold within 30 days and 211 funds added in the latest 13F quarter.
Febbo Phillip G.
Chief Scientific & Med Officer
SELL
2026-09-04 SEC
10,405
$446.3K
+18.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 2, 2026.
  • The trade is 7.7% of the 135,753 shares held after it.
  • 5 other insiders sold within 30 days.
  • 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific & Med Officer Febbo Phillip G. sold about $446.3K of VCYT under a 10b5-1 plan on Sep 4, 2026; 5 other insiders sold within 30 days and 211 funds added in the latest 13F quarter.
Febbo Phillip G.
Chief Scientific & Med Officer
SELL
2026-09-04 SEC
2,705
$118.1K
+18.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 2, 2026.
  • The trade is 2.0% of the 133,048 shares held after it.
  • 5 other insiders sold within 30 days.
  • 211 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific & Med Officer Febbo Phillip G. sold about $118.1K of VCYT under a 10b5-1 plan on Sep 4, 2026; 5 other insiders sold within 30 days and 211 funds added in the latest 13F quarter.
173 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 168 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$11.5M over 180 days
-$1.4M over 90 days
below 70% of Healthcare Services
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
211 funds bought in last quarter
more than 79% of Healthcare Services
Revenue
+16.0% year over year
more than 60% of Healthcare Services
Margin
12.8% net margin
more than 94% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
12.7% of the float short (float per yahoo 2026-10-26) · 5.9 days to cover · settled 2026-09-30
more than 88% of Healthcare Services
What changed in the last 30 days
Oct 20Director Bhanji Muna sold $81.5K under a 10b5-1 plan (Oct 19)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch VCYT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+41.1%12M
-16%+13%+41%+70%2025-102025-122026-022026-042026-062026-082026-10 2026-06-04 · Stapley Marc sold $6.9M2025-11-05 · JONES EVAN/ FA sold $1.1M2026-05-22 · Wygant Jonathan sold $1.1M2026-03-04 · Stapley Marc sold $953.4K2026-06-04 · Leite John sold $699.7K2026-03-04 · Stapley Marc sold $684.3K2025-12-05 · EASTHAM KARIN sold $587.1K2026-03-04 · Chambers Rebecca sold $506.5K2026-03-02 · Febbo Phillip G. sold $485.4K2025-11-05 · JONES EVAN/ FA sold $474.7K2025-12-16 · McGuire Annie sold $458.9K2026-09-04 · Febbo Phillip G. sold $446.3K2026-05-20 · EPSTEIN ROBERT S sold $440.1K2025-12-04 · Chambers Rebecca sold $397.9K2025-11-05 · EASTHAM KARIN sold $387.2K2025-11-20 · Holstein Jens sold $299.4K2025-11-05 · Chambers Rebecca sold $287.0K2025-12-05 · EASTHAM KARIN sold $284.6K2025-11-05 · JONES EVAN/ FA sold $264.7K2025-11-05 · McGuire Annie sold $258.6K2025-11-07 · Wygant Jonathan sold $233.9K2025-12-04 · Chambers Rebecca sold $224.0K2025-11-10 · Wygant Jonathan sold $216.0K2025-12-04 · Stapley Marc sold $208.6K2026-09-14 · Holstein Jens sold $204.7K2026-05-06 · McGuire Annie sold $204.1K2026-05-06 · McGuire Annie sold $194.1K2026-03-04 · Leite John sold $185.1K2026-03-04 · McGuire Annie sold $176.2K2026-06-18 · EASTHAM KARIN sold $168.9K2026-09-21 · Leite John sold $160.6K2026-03-04 · Chambers Rebecca sold $156.4K2025-12-04 · Stapley Marc sold $152.5K2025-11-25 · Leite John sold $140.4K2026-09-04 · Febbo Phillip G. sold $118.1K2026-09-04 · Chambers Rebecca sold $106.0K2026-06-04 · Chambers Rebecca sold $98.2K2026-09-04 · McGuire Annie sold $92.2K2026-06-04 · McGuire Annie sold $89.0K2026-10-19 · Bhanji Muna sold $81.5K2026-09-01 · Bhanji Muna sold $80.1K2026-06-04 · Chambers Rebecca sold $78.8K2026-09-24 · JENS HOLSTEIN filed to sell $352.5K2026-09-21 · JOHN LEITE filed to sell $159.8K2026-09-14 · JENS HOLSTEIN filed to sell $204.7K2026-09-04 · REBECCA CHAMBERS filed to sell $163.1K2026-09-04 · PHILLIP FEBBO filed to sell $585.6K2026-09-04 · ANN MCGUIRE filed to sell $145.4K2026-09-01 · MUNA BHANJI filed to sell $161.0K2026-06-18 · KARIN EASTHAM filed to sell $191.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VCYT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
13,486,437 sh
$792.1M
FMR LLC
7,702,746 sh
$452.4M
Artisan Partners Limited Partnership
5,538,404 sh
$325.3M
VANGUARD PORTFOLIO MANAGEMENT LLC
4,716,191 sh
$277.0M
STATE STREET CORP
4,698,128 sh
$276.0M

Congress trades in VCYT

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-11-12 · disclosed 33 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-06-16 · disclosed 24 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VCYT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JENS HOLSTEIN
Filed 2026-09-24
$352.5K
JOHN LEITE
Filed 2026-09-21
$159.8K
JENS HOLSTEIN
Filed 2026-09-14
$204.7K
REBECCA CHAMBERS
Filed 2026-09-04
$163.1K
PHILLIP FEBBO
Filed 2026-09-04
$585.6K

VCYT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust NYSE Arca Biotechnology Index Fund
$143.4M position · as of 2026-06-30
5.1%
Global X Genomics & Biotechnology ETF
$2.0M position · as of 2026-05-31
3.6%
ALGER WEATHERBIE SPECIALIZED GROWTH FUND
$6.9M position · as of 2026-07-31
2.9%
Oberweis Global Opportunities Fund
$2.0M position · as of 2026-06-30
2.7%
Invesco Biotechnology & Genome ETF
$7.3M position · as of 2026-07-31
2.6%
ARK Genomic Revolution ETF
$39.7M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Bonnie Anderson
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.4M
$9.6M
$2.8M
-14%
+25%
2024
$6.8M
$14.9M
$3.2M
-19%
-7%
2023
$7.2M
$9.6M
$2.7M
-44%
-6%
2022
$4.9M
$1.6M
$3.7M
-52%
-10%
2020
$4.6M
$15.5M
$2.2M
+75%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.5M sold by insiders over 180 days, 211 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $1.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

VCYT financials

Revenue growth
+16.0%
XBRL, annual
Net margin
12.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$561.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+20.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$166.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2021-12-31 (54 months older than the period end) plus current 2022-12-31 (42 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
+8.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+8.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+10.0%
operating income after a 1.3% effective tax rate, over long-term 2021-12-31 (54 months older than the period end) plus current 2022-12-31 (42 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+7.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
35.91x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$3.7B
market value at close 2026-10-27 on 2026-07-27 shares, plus long-term 2021-12-31 (54 months older than the period end) plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
FCF yield
+4.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
0.11x
P/E over trailing EPS growth of 324%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$517.1M$445.8M$361.1M$296.5M
Gross profit$362.5M$298.1M$229.7M$175.7M
Operating income$57.8M$16.1M-$85.8M-$41.1M
Net income$66.4M$24.1M-$74.4M-$36.6M
EPS (diluted)0.820.31-1.02-0.51
Operating cash flow$136.3M$75.1M$44.2M$7.5M
Cash$362.6M$239.1M$216.5M$154.2M
SEC XBRL, fiscal years, as known on 2026-10-28

VCYT Stock Sonar score 6/7 axes

Find similar shapesCompare

VCYT ranks highest on financial health (99th percentile) and profitability (63rd), and lowest on insider conviction (14th), among Healthcare Services peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
63
Inputs
  • Return on equity+8.8% · 64 pct, sector of 70
  • Return on assets+8.1% · 84 pct, sector of 88
  • Return on invested capital+10.0% · 41 pct, universe of 1,069
  • Return on capital employed+7.9% · 61 pct, sector of 68
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 61
  • Cash flow to debtno debt to cover
Growth
60
Inputs
  • Revenue growth, YoY+16.0% · 60 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
14
Inputs
  • Net Form 4 buying (codes P and S), 180d-$10.1M · 29 pct, sector of 64
  • Insider buyers, 180d0 · 0 pct, sector of 64
Institutional and government
60
Inputs
  • Funds adding, latest quarter211 · 79 pct, sector of 73
  • Congress net buyers, 365d0 · 40 pct, universe of 719
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
46
Inputs
  • Short interest, % of float+12.7% · 21 pct, sector of 95
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.6% · 70 pct, sector of 72
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VCYT filings, in plain words

Are Veracyte insiders buying or selling VCYT?

In the 180 days to 2026-10-28, Veracyte insiders were net sellers, a net $11.5M across purchases and sales reported on Form 4, by 10 sellers.

Have members of Congress traded VCYT?

Yes. In the year to 2026-10-28, 1 House member disclosed buying VCYT and 1 House member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-03-03.

Are there planned insider sales of VCYT?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.8M of stock; the latest, by JENS HOLSTEIN, was filed 2026-09-24.

Read the full summary

In the 180 days to 2026-10-28, Veracyte insiders were net sellers of VCYT, a net $11.5M across purchases and sales reported on Form 4 by 10 sellers. 45% of the 22 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying VCYT and 1 member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-03-03. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies